CRSP - Crispr Therapeutics: Upcoming Catalysts May Validate The Bull Thesis And Force A Change In Plans

2024-03-30 03:03:34 ET

Summary

• CRISPR Therapeutics has a diverse pipeline of gene therapies and strategic partnerships, positioning it at the forefront of life science innovation.
• The approval of CASGEVY, the first CRISPR-based medicine, for transfusion-dependent ?-thalassemia and sickle cell disease, signifies a significant milestone for the company.
• The company has upcoming catalysts, including updates on CASGEVY, the CTX112 program, CTX131, CTX211, CTX310, CTX320, and undisclosed targets, which could validate its technology and drive value creation.

It has been over 4 years since my last CRISPR Therapeutics ( CRSP ) article when I was hesitant about gathering a heavy CRSP position due to the ticker’s premium valuation, volatility, and the company’s young pipeline. Yet, I was optimistic about the company’s prospects of their expansive pipeline, and partnerships. Despite my concerns, I decided to initiate a long-term investment to gain exposure to the gene editing industry and benefit from an early entry ahead of numerous catalysts slated over the next several years. At that time, CRSP was around the $40 per share level, and I have enjoyed following the price movements and catalysts to secure profits from a volatile ticker. Eventually, my CRSP position obtained a “House Money” status and I ceased all transactions as the ticker remained above my Buy Threshold. Now that CRISPR has an approved product and has some potent catalysts on the docket, I am forced to modify my plans for my dormant position and reassess my bull thesis....

For further details see: